FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to chemical and pharmaceutical industry and represents methods for treating solid cancer, enhancing the antitumor effect in patients with solid cancers and a method for treating a patient with solid cancer received irinotecan hydrochloride hydrate, wherein the combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5, is administered to a patient with solid cancer in a dosage range of 35 to 70 mg/m2/day by the amount of trifluridine, and irinotecan hydrochloride hydrate is administered in a dosage range from 45 to 144 mg/m2/day. Invention is also a method for treating solid cancers, where the combination drug containing trifluridine and tyirycil hydrochloride in a molar ratio of 1:0.5 is administered in combination with irinotecan hydrochloride hydrate, where the dosage of the combination drug containing trifluridine and tyirycil hydrochloride in a molar ratio of 1:0.5 is 50 % to 100 % of the recommended dose in the monotherapy, and the dose of irinotecan hydrochloride hydrate is 25 % to 80 % of the recommended dose in the monotherapy.
EFFECT: group of inventions provides the enhanced antitumor effect of the combination drug, as well as the reduced side effects due to the use of relatively smaller amounts of active agents.
18 cl, 7 dwg, 3 tbl, 2 ex
